Literature DB >> 28248313

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.

C N Harrison, A M Vannucchi, J-J Kiladjian, H K Al-Ali, H Gisslinger, L Knoops, F Cervantes, M M Jones, K Sun, M McQuitty, V Stalbovskaya, P Gopalakrishna, T Barbui.   

Abstract

Entities:  

Year:  2017        PMID： 28248313     DOI： 10.1038/leu.2016.323

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

Review 1.  Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions.

Authors:  Ruochen Jia; Robert Kralovics
Journal:  Int J Hematol       Date:  2019-11-18       Impact factor: 2.490

2.  Guidance on changing therapy choice in myelofibrosis.

Authors:  Donal P McLornan; Claire N Harrison
Journal:  Blood Adv       Date:  2020-02-25

3.  Novel lysyl oxidase inhibitors attenuate hallmarks of primary myelofibrosis in mice.

Authors:  Orly Leiva; Seng Kah Ng; Shinobu Matsuura; Vipul Chitalia; Hector Lucero; Alison Findlay; Craig Turner; Wolfgang Jarolimek; Katya Ravid
Journal:  Int J Hematol       Date:  2019-10-21       Impact factor: 2.490

4.  Inflammation-driven activation of JAK/STAT signaling reversibly accelerates acute myeloid leukemia in vitro.

Authors:  Jan Habbel; Lucas Arnold; Yiyang Chen; Michael Möllmann; Kirsten Bruderek; Sven Brandau; Ulrich Dührsen; Maher Hanoun
Journal:  Blood Adv       Date:  2020-07-14

Review 5.  Fatal Disseminated Tuberculosis and Concurrent Disseminated Cryptococcosis in a Ruxolitinib-treated Patient with Primary Myelofibrosis: A Case Report and Literature Review.

Authors:  Asuka Ogai; Kazuma Yagi; Fumimaro Ito; Hideharu Domoto; Tetsuya Shiomi; Kenko Chin
Journal:  Intern Med       Date:  2021-09-25       Impact factor: 1.282

6.  Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.

Authors:  Claire N Harrison; Adam J Mead; Anesh Panchal; Sonia Fox; Christina Yap; Emmanouela Gbandi; Aimee Houlton; Samah Alimam; Joanne Ewing; Marion Wood; Frederick Chen; Jason Coppell; Nicki Panoskaltsis; Steven Knapper; Sahra Ali; Angela Hamblin; Robyn Scherber; Amylou C Dueck; Nicholas C P Cross; Ruben Mesa; Mary Frances McMullin
Journal:  Blood       Date:  2017-08-09       Impact factor: 22.113

7.  MPL overexpression induces a high level of mutant-CALR/MPL complex: a novel mechanism of ruxolitinib resistance in myeloproliferative neoplasms with CALR mutations.

Authors:  Shunichiro Yasuda; Satoru Aoyama; Ryoto Yoshimoto; Huixin Li; Daisuke Watanabe; Hiroki Akiyama; Kouhei Yamamoto; Takeo Fujiwara; Yuho Najima; Noriko Doki; Emiko Sakaida; Yoko Edahiro; Misa Imai; Marito Araki; Norio Komatsu; Osamu Miura; Norihiko Kawamata
Journal:  Int J Hematol       Date:  2021-06-24       Impact factor: 2.490

Review 8.  Patterns of Ruxolitinib Therapy Failure and Its Management in Myelofibrosis: Perspectives of the Canadian Myeloproliferative Neoplasm Group.

Authors:  Vikas Gupta; Sonia Cerquozzi; Lynda Foltz; Christopher Hillis; Rebecca Devlin; Mahmoud Elsawy; Kuljit Grewal; Caroline Hamm; Caroline McNamara; Shireen Sirhan; Brian Leber
Journal:  JCO Oncol Pract       Date:  2020-03-05

9.  Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea.

Authors:  Annalisa Pacilli; Giada Rotunno; Carmela Mannarelli; Tiziana Fanelli; Alessandro Pancrazzi; Elisa Contini; Francesco Mannelli; Francesca Gesullo; Niccolò Bartalucci; Giuditta Corbizi Fattori; Chiara Paoli; Alessandro M Vannucchi; Paola Guglielmelli
Journal:  Blood Cancer J       Date:  2018-11-22       Impact factor: 11.037

Review 10.  Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors.

Authors:  Grzegorz Helbig
Journal:  Med Oncol       Date:  2018-08-03       Impact factor: 3.064
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.